KNSAKiniksa Pharmaceuticals International, plc
$79.76+125% 1Y
$79.76
$35.5152 weeks$80.83
The financials
Kiniksa Pharmaceuticals International, plc by the numbers
Kiniksa Pharmaceuticals International, plc (KNSA) reported revenue of $214M in Q1 2026 (quarter ended Mar 31, 2026), up 56% from the same quarter a year earlier. That came with a gross margin of 90% and net income of $23M (11% of revenue). For the full year FY2025, revenue was $678M (+60% year on year) and net income $59M. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $214M | $138M | +56% |
| Gross profit | $193M | $120M | +61% |
| Operating income | $29M | $13M | +121% |
| Net income | $23M | $8.5M | +165% |
| Diluted EPS | $0.27 | $0.11 | +145% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $0.00
Segment Latestyear on year
- Collaboration$0.00$0.00year on year n/an/a
Drug Manufacturers, Specialty & Generic
Ranks #28 of 41 by RyuScore